Community-Acquired Pneumonia in Adults: Evolving Epidemiology and Advances in Diagnosis, Treatment, and Prevention

Community-acquired pneumonia (CAP) remains a major cause of hospitalization and death among adults, yet its clinical landscape is changing. This narrative review examines evidence published primarily between 2023 and October 2026 on epidemiology, diagnosis, treatment, and prevention of adult CAP. Post-pandemic surveillance indicates substantial regional shifts in CAP incidence, respiratory pathogen circulation, and pneumococcal serotype distribution, although the persistence of these trends remains uncertain. Updated guidelines recognize lung ultrasonography as an alternative to chest radiography in settings with adequate expertise. AI-assisted chest radiography supports diagnostic assessment, while metagenomic next-generation sequencing may improve pathogen identification in selected patients with severe CAP. Randomized trials show that rapid multiplex molecular testing increases etiologic detection and may accelerate pathogen-directed treatment, but reductions in antibiotic exposure and improvements in patient-centered outcomes have not been consistent. Treatment advances include shorter antibiotic courses for clinically stable nonsevere CAP, biomarker-assisted discontinuation in selected patients, and conditional use of systemic corticosteroids for severe CAP. Evidence for clarithromycin-associated early response and host-directed immunomodulation requires further validation of clinical benefits and patient selection. Higher-valency pneumococcal conjugate vaccines broaden serotype coverage, whereas evidence directly demonstrating superior protection against clinically confirmed CAP remains limited. These developments favor selective application of diagnostic tools, individualized treatment decisions, and continued pathogen-specific surveillance, with future research prioritizing safety and clinically meaningful outcomes.

Authors

Institutions

Publication Details

Journal
Journal of Clinical Question
Published
2026-11-21
DOI
https://doi.org/10.69854/jcq.2026.0037
Primary Topic
Pneumonia and Respiratory Infections
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Community-Acquired Pneumonia in Adults: Evolving Epidemiology and Advances in Diagnosis, Treatment, and Prevention

Hongmei Piao, Qiuling Chen, Yujie Zhang
1 links
Journal of Clinical Question
Pneumonia and Respiratory Infections
article

Community-Acquired Pneumonia in Adults: Evolving Epidemiology and Advances in Diagnosis, Treatment, and Prevention

Hongmei Piao, Qiuling Chen, Yujie Zhang
article en

Abstract

Community-acquired pneumonia (CAP) remains a major cause of hospitalization and death among adults, yet its clinical landscape is changing. This narrative review examines evidence published primarily between 2023 and October 2026 on epidemiology, diagnosis, treatment, and prevention of adult CAP. Post-pandemic surveillance indicates substantial regional shifts in CAP incidence, respiratory pathogen circulation, and pneumococcal serotype distribution, although the persistence of these trends remains uncertain. Updated guidelines recognize lung ultrasonography as an alternative to chest radiography in settings with adequate expertise. AI-assisted chest radiography supports diagnostic assessment, while metagenomic next-generation sequencing may improve pathogen identification in selected patients with severe CAP. Randomized trials show that rapid multiplex molecular testing increases etiologic detection and may accelerate pathogen-directed treatment, but reductions in antibiotic exposure and improvements in patient-centered outcomes have not been consistent. Treatment advances include shorter antibiotic courses for clinically stable nonsevere CAP, biomarker-assisted discontinuation in selected patients, and conditional use of systemic corticosteroids for severe CAP. Evidence for clarithromycin-associated early response and host-directed immunomodulation requires further validation of clinical benefits and patient selection. Higher-valency pneumococcal conjugate vaccines broaden serotype coverage, whereas evidence directly demonstrating superior protection against clinically confirmed CAP remains limited. These developments favor selective application of diagnostic tools, individualized treatment decisions, and continued pathogen-specific surveillance, with future research prioritizing safety and clinically meaningful outcomes.

Journal of Clinical QuestionVol. 3(6)
Yanbian University (CN), Yanbian University Hospital (CN)
Good health and well-being
Pneumonia and Respiratory Infections
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon
Community-Acquired Pneumonia in Adults: Evolving Epidemiology and Advances in Diagnosis, Treatment, and Prevention — Hongmei Piao, Qiuling Chen, et al. · Journal of Clinical Question (2026) | TGRS Research Map | TGRS